drugset
drugset / Trial / NCT07513233

Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL)

NCT07513233 ↗

Phase 1 Recruiting 92 enrolled Capital Medical University
Non-randomizedSequentialOpen-labelTreatment

Summary

This study is an investigator-initiated Phase 1b clinical trial employing an open-label, non-randomized, dose-escalation design. The primary objective is to evaluate the safety and tolerability of the investigational intervention and to determine the recommended dose for subsequent clinical studies.

Timeline

Start
2026-04-28
Primary completion
2026-08-01
Completion
2026-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Anisodine Hydrobromide Small molecule 1 mg Intravenous
Subject Anisodine Hydrobromide Small molecule 1.5 mg Intravenous
Subject Anisodine Hydrobromide Small molecule 2 mg Intravenous
Subject Anisodine Hydrobromide Small molecule 2.5 mg Intravenous

Indications

ischemic stroke